Last updated: February 23, 2026
What is the Drug with NDC 00121-0721?
The National Drug Code (NDC) 00121-0721 corresponds to Zolgensma (onasemnogene abeparvovec-xioi). Approved by the FDA in May 2019, Zolgensma is a gene therapy indicated for pediatric patients less than two years old with spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene.
Market Landscape of SMA Treatments
Key Competitors
| Drug Name |
Type |
Approval Date |
Indication |
Price (List) |
| Zolgensma |
Gene therapy |
2019 |
SMA in children under 2 |
$2.1 million (single dose) |
| Spinraza (nusinersen) |
Antisense oligonucleotide |
2016 |
SMA in broader age groups |
$125,000 per dose (initial dose) |
| Evrysdi (risdiplam) |
Oral SMN2 splicing modifier |
2020 |
SMA in infants and older children |
$340,000 annually |
Market Size and Penetration
In 2022, the global SMA market was estimated at $1.2 billion, with the US accounting for over 75%. Zolgensma's market share in 2022 exceeded 60% among gene therapy options, driven by its single-dose administration and early approval for pediatric populations.
Regulatory and Reimbursement Environment
Reimbursement for high-cost gene therapies relies on health technology assessments, with insurers demanding evidence of cost-effectiveness. The Institute for Clinical and Economic Review (ICER) reported a value-based price cap around $1.75 million, slightly below the list price, considering long-term benefits and reduced healthcare costs.
Price Projections
Short-Term (Next 1-2 Years)
- Market stabilization at list price: Given the high initial pricing and reimbursement negotiations, prices are unlikely to significantly decrease.
- Potential discounts: Manufacturers may offer contract-based discounts or outcomes-based agreements to facilitate payer coverage.
Medium to Long-Term (3-5 Years)
- Price erosion: As manufacturing efficiencies improve and biosimilar-like gene therapies enter the market, prices could decline by 10-20%.
- Competitive pressures: Emerging SMA gene therapies may exert downward pressure on Zolgensma pricing, especially if other therapies demonstrate comparable efficacy at lower costs.
Price Trends Summary
| Year |
Expected Price Range |
Factors Influencing Price |
| 2023-2024 |
$2.0M - $2.2M |
Contract negotiations, payer pushback |
| 2025-2027 |
$1.8M - $2.0M |
Market entry of competitors, manufacturing improvements |
| 2028-2030 |
$1.5M - $1.8M |
Biosimilar development, policy shifts |
Regulatory and Manufacturing Impact
Advances in production technology could lower manufacturing costs, which, combined with volume growth, may lead to price reductions. Policy shifts emphasizing value-based pricing further influence equilibrium prices.
Status of Patent and Exclusivity
Zolgensma's patent protection extends through the late 2020s, delaying biosimilar entry. Patent litigation and orphan drug exclusivity support premium pricing for several more years.
Conclusion
NDC 00121-0721 (Zolgensma) commands a high initial price aligned with its novel gene therapy status. Market growth is driven by increasing diagnosis rates and expanding age indications, but pricing pressures from competitors, biosimilar development, and policy considerations anticipate modest reductions over the next decade.
Key Takeaways
- Zolgensma remains the most expensive treatment among SMA therapies, priced at $2.1 million per dose.
- The SMA treatment market is growing, with an estimated value of $1.2 billion in 2022.
- Reimbursement strategies and health technology assessments influence net prices, often resulting in discounts.
- Price reductions of 10-20% are expected over the next five years, driven by manufacturing efficiencies and market competition.
- Patent protection shields pricing through at least 2027, with biosimilar entry anticipated afterward.
FAQs
1. What factors sustain Zolgensma’s high price?
The therapy's one-time administration, complex manufacturing, and lack of direct biosimilar competition sustain its premium cost.
2. How does reimbursement impact Zolgensma’s market access?
Reimbursement depends on value assessments, with payers negotiating discounts or outcomes-based agreements to offset high upfront costs.
3. Are there biosimilars for Zolgensma?
As of 2023, no biosimilars are approved yet, but biosimilar development is ongoing with potential entry after patent expiry, expected around 2027-2028.
4. How does the SMA market growth affect the pricing outlook?
Expanding diagnosis rates and broader indications increase volume, which could incentivize pricing negotiations to facilitate broader access.
5. What role do international markets play in pricing projections?
Pricing outside the US varies widely due to differing regulatory and reimbursement policies, often lower than US prices.
References
[1] Food and Drug Administration. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval.
[2] IQVIA. (2022). Global SMA market report.
[3] Institute for Clinical and Economic Review. (2022). SMA gene therapies value assessment.
[4] Fierce Pharma. (2023). Biosimilar pipeline for gene therapies.
[5] U.S. Patent and Trademark Office. (2022). Patent status and legal challenges for Zolgensma.
